5 Undervalued Defensive Stocks For 2023

4. Pfizer Inc. (NYSE:PFE)

PE Ratio as of January 27: 8.43

Pfizer Inc. (NYSE:PFE) is under pressure amid downgrades from Wall Street analysts who fear short-term challenges as we near the end of the COVID-19 pandemic. However, Pfizer Inc. (NYSE:PFE) remains one of the most stable and defensive companies. Pfizer Inc. (NYSE:PFE) has strong balance sheet and its pipeline is full of promising products. Pfizer Inc. (NYSE:PFE) has at least 19 near-term or expected product launches. These products can add approximately $20 billion in revenues in 2030. Some of Pfizer Inc. (NYSE:PFE)’s promising products are related to hematology, sickle cell disease, and obesity.

Pfizer Inc. (NYSE:PFE) is also a strong defensive player in recessions due to its dividend payments. Pfizer Inc. (NYSE:PFE) has upped its dividends consistently for over a decade now.

While we are nearing the end of the COVID-19 pandemic, there’s no surety that the world will be free of pandemics in the future. On that front, Pfizer Inc. (NYSE:PFE)’s is expanding its mRNA vaccine segment and expects to rake in $10 billion to $15 billion annually from this segment in the long term.